EUVIMEDEUVIMED entdecken
Open Access · CC BY-ND 4.0

PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE

Muhammad Asif Rasheed, Muhammad Suhail Amin, Muhammad Sohaib Nadeem, Muhammad Nadeem Chaudhry, Areej Fatima

Journal of Ayub Medical College Abbottabad · 2024

DOI: 10.55519/jamc-03-13367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ayub Medical College Abbottabad, 2024. Verfasst von Muhammad Asif Rasheed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Combined Military Hospital, Rawalpindi-Pakistan. Hauptthemen laut MEDLINE: Denosumab, Giant Cell Tumor of Bone, Bone Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Giant cell tumour of bone (GCTB) is a rare, locally aggressive benign bone tumour with slight female sex predilection and affecting young adults 20-40 years of age. World health organization (WHO) has recently categorized GCTB as an intermediate malignant tumour. GCTB is known to be driven pathologically via expression of pro-osteoclastic signals by stromal cells. This is mediated precisely via the expression of RANKL by stromal cells acting in an autocrine fashion on RANK receptor-positive osteoclast-like giant cells and their precursors. While the treatment is primarily surgical, we hypothesized that preoperative denosumab therapy facilitates conversion to a less morbid procedure in an aggressive campanacci grade 3 GCTB, otherwise amenable to joint resection and reconstruction/arthrodesis.

Methods

A prospective, single arm, interventional study was conducted in Orthopaedics and radiation oncology department of combined military hospital (CMH) Rawalpindi. The duration of study was 36 months. Patients were recruited by purposive sampling technique as per inclusion/exclusion criteria. Denosumab was administered as preoperative adjuvant therapy for 3 months. Pain was assessed utilizing Brief Pain Inventory -Short Form (BPI-SF) and functional status was assessed as per Musculoskeletal tumour society score at baseline and 12 weeks after commencement of denosumab therapy. The intent of surgery pre and post denosumab therapy was ascertained.

Results

Total of 23 patients were a part of this study. Mean pain scores and MSTS scores prior to and after denosumab were statistically significant with p-value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabGiant Cell Tumor of BoneBone NeoplasmsHumansFemaleAdultMaleProspective StudiesBone Density Conservation AgentsYoung AdultFeasibility StudiesNeoplasm StagingPreoperative Care

Stichwörter der Autor:innen

Curettage; Denosumab; Giant cell tumour of bone

Substanzen

DenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Combined Military Hospital, Rawalpindi-Pakistan.

Zitieren

APA

Rasheed, M. A., Amin, M. S., Nadeem, M. S., Chaudhry, M. N., & Fatima, A. (2024). PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE. Journal of Ayub Medical College Abbottabad. https://doi.org/10.55519/jamc-03-13367

Vancouver

Rasheed MA, Amin MS, Nadeem MS, Chaudhry MN, Fatima A. PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE. Journal of Ayub Medical College Abbottabad. 2024. doi:10.55519/jamc-03-13367

BibTeX
@article{Rasheed2024,
  author = {Rasheed, Muhammad Asif and Amin, Muhammad Suhail and Nadeem, Muhammad Sohaib and Chaudhry, Muhammad Nadeem and Fatima, Areej},
  title = {PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE},
  journal = {Journal of Ayub Medical College Abbottabad},
  year = {2024},
  doi = {10.55519/jamc-03-13367}
}
Kostenlos starten →